Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.045
Sell
RSI(14)
24.620
Sell
STOCH(KDJ)(9,3,3)
21.992
Buy
ATR(14)
0.067
High Vlolatility
CCI(14)
-126.731
Sell
Williams %R
85.139
Oversold
TRIX(12,20)
-0.955
Sell
StochRSI(14)
0.000
Oversold
Search
IN8BIO, Inc.
INABAdd to Watchlist
1.035USD
-0.045-4.17%
Close 07-31 16:00（ET）Quotes delayed by 15 min
10.19MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-4.17%
5 Days
-13.75%
1 Month
-26.60%
6 Months
-47.46%
Year to Date
-55.77%
1 Year
-51.41%
Key Figures
1.080Open
1.080High
57.63KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.59%Turnover Ratio
1.080Prev. Close
1.010Low
33.69KTurnover
LossP/E Static
0.45P/B
0.00%Div Yield TTM
-82.28%ROA
5.61052wk High
1.02Volume Ratio
-30.44MNet Profit
9.85MShares
-2.7112EPS TTM
0.15Beta
-103.55%ROE
1.17052wk Low
6.48%Amplitude
--Gross Margin
10.19MMarket Cap
-4.59Reward/Risk
5.21%Risk Rate
IN8BIO, Inc. News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
4
analysts
Buy
Current Rating
6.250
Target Price
+484.11%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
IN8BIO, Inc.
INAB
4
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
1.097
Sell
MA10
1.160
Sell
MA20
1.271
Sell
MA50
1.419
Sell
MA100
1.493
Sell
MA200
1.703
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
IN8BIO, Inc. Info
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
Ticker SymbolINAB
CompanyIN8BIO, Inc.
CEOHo (William T)
Websitehttps://www.in8bio.com
Shareholders
Related Instruments
-0.53%
+0.23%
-1.00%
-2.54%
+0.33%
-1.44%
-0.61%
-0.79%
-8.78%
+0.48%
+0.70%
-1.00%
-0.69%
+0.49%
-1.08%
+3.32%
0.00%
+1.34%
-0.87%
-2.17%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.640
-24.790 (-7.43%)
200.760
+5.720 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of IN8BIO, Inc. (INAB)?
The current price of IN8BIO, Inc. (INAB) is 1.03.
What is the symbol of IN8BIO, Inc.?
The ticker symbol of IN8BIO, Inc. is INAB.
What is the 52-week high of IN8BIO, Inc.?
The 52-week high of IN8BIO, Inc. is 5.61.
What is the 52-week low of IN8BIO, Inc.?
The 52-week low of IN8BIO, Inc. is 1.17.
What is the market capitalization of IN8BIO, Inc.?
The market capitalization of IN8BIO, Inc. is 10.19M.
Is IN8BIO, Inc. (INAB) currently rated as Buy, Hold, or Sell?
According to analysts, IN8BIO, Inc. (INAB) has an overall rating of Buy, with a price target of 6.25.
What is the Earnings Per Share (EPS TTM) of IN8BIO, Inc. (INAB)?
The Earnings Per Share (EPS TTM) of IN8BIO, Inc. (INAB) is -4.44.